



PROVIDING ANSWERS FOR CANCER PATIENTS

Press release

8 November, 2024

Curasight to present at Dansk Aktionærforening InvestorDagen

Copenhagen, Denmark, 8 November 2024 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CMO Andreas Kjær have been invited to present the company's latest progress and strategy at Dansk Aktionærforening InvestorDagen in Copenhagen 11 November 2024

Management will give an overall update on the company's pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating cancer, and its view on the newly published peer-reviewed data in the journal EJMIMI Research from the Phase II uTRACE trial in brain cancer and its impact for the Curasight clinical development strategy.

The Dansk Aktionærforening InvestorDagen presentation will be recorded 14:05 - 14:30 (CET), Monday 11 November 2024.

Should you be unable to attend the event, a link to the presentation will be made available on Curasight's website, after the event.

For more information – please [click here](#)

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE[®]) and Radioligand Therapy (uTREAT[®]) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.